HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 15, 11030-11037, April 13, 2007

This Article Abstract Full Text (PDF) All Versions of this Article: 282/15/11030    most recent M700287200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schromm, A. B. Articles by Brandenburg, K. Search for Related Content PubMed PubMed Citation Articles by Schromm, A. B. Articles by Brandenburg, K. Social Bookmarking                      What's this?

Physicochemical and Biological Analysis of Synthetic Bacterial Lipopeptides

VALIDITY OF THE CONCEPT OF ENDOTOXIC CONFORMATION^*

Andra B. Schromm¹, Jörg Howe^¶, Artur J. Ulmer^||, Karl-Heinz Wiesmüller^**, Tobias Seyberth, Günther Jung, Manfred Rössle, Michel H. J. Koch, Thomas Gutsmann^¶, and Klaus Brandenburg^¶

From the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Department of Immunochemistry and Biochemical Microbiology, Emmy Noether Group of Immunobiophysics, ^¶Division of Biophysics, ^||Division of Immunology, 23845 Borstel, Germany, ^**EMC Microcollections GmbH, 72070 Tübingen, Germany, Institute of Organic Chemistry, University of Tübingen, 72076 Tübingen, Germany, and European Molecular Biology Laboratory c/o DESY, Notkestrasse 85, 22603 Hamburg, Germany

Received for publication, January 10, 2007 , and in revised form, February 15, 2007.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The importance of the biological function and activity of lipoproteins from the outer or cytoplasmic membranes of Gram-positive and Gram-negative bacteria is being increasingly recognized. It is well established that they are like the endotoxins (lipopolysaccharide (LPS)), which are the main amphiphilic components of the outer membrane of Gram-negative bacteria, potent stimulants of the human innate immune system, and elicit a variety of proinflammatory immune responses. Investigations of synthetic lipopeptides corresponding to N-terminal partial structures of bacterial lipoproteins defined the chemical prerequisites for their biological activity and in particular the number and length of acyl chains and sequence of the peptide part. Here we present experimental data on the biophysical mechanisms underlying lipopeptide bioactivity. Investigation of selected synthetic diacylated and triacylated lipopeptides revealed that the geometry of these molecules (i.e. the molecular conformations and supramolecular aggregate structures) and the preference for membrane intercalation provide an explanation for the biological activities of the different lipopeptides. This refers in particular to the agonistic or antagonistic activity (i.e. their ability to induce cytokines in mononuclear cells or to block this activity, respectively). Biological activity of lipopeptides was hardly affected by the LPS-neutralizing antibiotic polymyxin B, and the biophysical interaction characteristics were found to be in sharp contrast to that of LPS with polymyxin B. The analytical data show that our concept of "endotoxic conformation," originally developed for LPS, can be applied also to the investigated lipopeptide and suggest that the molecular mechanisms of cell activation by amphiphilic molecules are governed by a general principle.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Beside lipopolysaccharides (LPS,² endotoxin), which are the major amphiphilic components of the outer membrane of Gram-negative bacteria, other amphiphilic molecules such as lipoproteins and lipopeptides (LP) are found in the cell wall of a large number of microorganisms, including Gram-negative as well as Gram-positive bacteria, mycobacteria, mycoplasms, and spirochetes (1–5). Like LPS these molecules can be potent activators of lymphocytes and macrophages and give danger signals to the infected host (6, 7). A variety of biological activities have been described for native LP as well as for synthetic LP based on the highly conserved lipopeptide moiety of Braun's lipoprotein derived from Escherichia coli (8). The innate immune system plays an essential role in the host defense against bacterial infection. Recognition of bacterial virulence factors is mandatory for the initiation of an inflammatory and anti-bacterial immune response. Bacterial compounds such as LPS and lipoproteins are recognized by type I transmembrane proteins of the Toll-like receptor (TLR) family (9). Of the more than 10 known TLRs, several have been found to participate in the recognition of microbial infections. TLR4 initiates cell activation by LPS in concert with the extracellular protein MD-2 (10–12). TLR4/MD-2 has been found to associate in complexes that include a variety of accessory proteins such as CD14, CD11/CD18, CD55, hsp70, hsp90, GDF5, and CXCR4 (13–20), MOE-SIN (21), the potassium channel MaxiK (22), and a membrane-associated form of LBP (23, 24). For TLR2, a variety of different ligands has been described, including lipoteichoic acid, lipoarabinomannan, bacterial lipoproteins/lipopeptides, and also some LPS variants from Gram-negative bacteria, yeast, spirochetes, and fungi (25). TLR2 has also been shown to associate with coreceptors (26). Together with Dectin-1, it recognizes infections by yeasts (27, 28) and mycobacteria (29). Via heteromeric receptor complexes with TLR1 and -6, TLR2 also recognizes a variety of bacterial lipopeptides (30–32). Recently, it was suggested that CD36 may have a role in the recognition of the diacylated bacterial lipopeptide MALP-2 (33).

As far as the structural prerequisites for bioactivity of lipopeptides are concerned, it has been shown that tripalmitoyl-S-glyceryl-L-Cys-Ser-Lys-Lys-Lys-Lys (Pam₃CSK₄) was highly active, whereas the natural dipeptide part of the outer membrane lipoprotein, tripalmitoyl-S-glyceryl-L-Cys-Ser (Pam₃CS), only has a low activity (34, 35). It is known for many amphiphilic molecules like phospholipids and glycolipids that physical parameters are strong determinants of biological activity. Above a certain threshold concentration, i.e. the critical micellar concentration, these molecules form aggregates in aqueous dispersions, which may adopt different phase states as follows: an ordered gel phase, where the acyl chains are in the all-trans (zig-zag) conformation, and a liquid crystalline phase, where the chains are disordered as a result of the introduction of gauche conformers. Between these phases a reversible first order transition takes place at a lipid-specific temperature. Furthermore, the type of aggregate structure, uni- and multilamellar, cubic direct or inverted, hexagonal H_I or inverted H_II, may play a decisive role in biological systems (36). It has been shown for LPS and its lipid moiety, lipid A, the endotoxic principle of LPS (37), that the aggregation type is essential for the expression of bioactivity, and that the state of order of the acyl chains may be a modulator of bioactivity (38–39). For lipopeptides, only for the immunoadjuvants Pam₃-L-Cys and Pam₃-L-Cys-Ser, experimental data are available, indicating that these molecules form vesicular or tubular aggregates of different sizes in aqueous dispersion depending on the configuration of the glycerol moiety and the head group (40). Furthermore, two Pam₃Cys-peptides LP1 and LP2, characterized by fluorescence correlation spectroscopy, form large and highly heterogeneous aggregates where the smaller aggregates were shown to have higher bioactivity.³ To clarify the correlation between physicochemical characteristics and biological activities, we have investigated three selected lipopeptides with different cytokine-inducing activity, with strong agonistic as well as antagonistic activity in human mononuclear cells.

We have found that as in the case of endotoxins, the types of aggregate structures are important determinants of cytokine-inducing activity. Furthermore, we show that our concept of "endotoxic conformation," which was shown to be applicable so far not only to LPS but also to particular synthetic phospholipids (41, 42), can also be extended to the lipopeptides. In addition, we present data showing that a biologically inactive lipopeptide, which antagonizes cell activation by biologically active lipopeptides, is also able to antagonize cell activation by LPS, supporting the broad validity of the conformation concept for agonistic as well as antagonistic activity.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Synthesis—Pam₂CSK₄ and Pam₃CSK₄ were synthesized and analyzed by EMC microcollections GmbH according to published procedures (43–45). The synthesis and analysis of the lipolanthionine peptide are described elsewhere in detail (46). The structural formula of the synthetic compounds dipalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)₄ (Pam₂CSK₄), tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)₄ (Pam₃CSK₄), and of the lipolanthionine peptide (2R,6R)-Pam₂LanHda-Ser-(Lys)₄-NH₂ (lipolan) are shown in Fig. 1. The stereochemistry and composition of the lipid tails of lipolan have been optimized for the inhibition of TLR2-dependent IL-8 induction by Pam₃CSK₄ in myelomonocytic THP-1 cells (46).

View larger version (14K): [in this window] [in a new window]   FIGURE 1. Chemical structures of synthetic Pam2CSK4, Pam3CSK4, and lipolan.

Lipid Sample Preparation—All lipid samples were prepared as aqueous suspensions in 20 mM HEPES, pH 7. For this, the lipids were suspended directly in buffer, thoroughly vortexed, temperature-cycled three times between 4 and 56 °C to enable the formation of stable aggregates and then stored for at least 12 h before measurement. To guarantee physiological conditions, the water content of the samples was usually around 95%. For preparations of liposomes from a mixture corresponding to the phospholipid composition of the macrophage membrane (phosphatidylcholine, phosphatidylserine, PE, and sphingomyelin in a molar ratio of 1:0.4:0.7:0.5), the lipids were solubilized in chloroform; the solvent was evaporated under a stream of nitrogen, and the lipids were resuspended in the appropriate volume of PBS, pH 7.0, and temperature-cycled as described above. Electron microscopy (kindly performed by H. Kühl, Division of Pathology, Forschungszentrum Borstel) revealed large multilamellar liposomes.

Activation of Human Mononuclear Cells and Macrophages—Mononuclear cells were isolated from human peripheral blood of healthy donors by the Ficoll-Histopaque gradient method and cultivated at 37 °C with 6% CO₂ in Teflon bags in RPMI 1640 medium (endotoxin 0.01 EU/ml; Biochrom, Berlin, Germany) containing 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 4% heat-inactivated human serum type AB from healthy donors. Cells were cultured in the presence of 2 ng/ml macrophage colony-stimulating factor for 7 days to differentiate monocytes to macrophages. To determine cytokine induction after cell stimulation, mononuclear cells were seeded in 200-µl aliquots of a suspension of 5 x 10⁶ cells/ml, and macrophages were seeded at 1 x 10⁶ cells/ml in 96-well tissue culture dishes (Nunc, Wiesbaden, Germany) in RPMI 1640 medium containing 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, with or without 4% human serum, and stimuli were added as indicated in the respective experiments. Cell-free supernatants were collected 4 h after stimulation and stored at –20 °C until determination of cytokine content. Data shown are mean ± S.D. of triplicate samples of one experiment and representative of at least three independent experiments.

Antagonistic Action of the Inactive Lipopeptide—Inactive lipopeptides, i.e. compounds that did not induce any cytokines in human mononuclear cells, were investigated with respect to their ability to block the LPS-induced TNF production in human macrophages. For this, Re LPS from S. minnesota R595 was prepared in three concentrations of 0.5, 1, and 5 ng/ml, and the agonistically inactive lipopeptide was added at a concentration of 1 µg/ml, and the TNF production of the macrophages was determined.

Transient Transfection and Stimulation of HEK293 Cells—HEK293 cells were plated at a density of 1.5 x 10⁵ cells/ml in 96-well plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 0.5 unit/ml penicillin, and 0.5 µg/ml streptomycin. The following day, cells were transiently transfected using Polyfect (Qiagen, Hilden, Germany) according to the manufacturer's protocol and plasmids containing huTLR4, huMD2, and/or huCD14 as described elsewhere (30). After 6 h of transfection cells were washed and stimulated with LPS at the indicated concentrations in the absence or presence of 10 µM lipolan for a further 24 h. Cell-free supernatants were collected and stored at –20 °C until determination of cytokine content. Data shown are the mean ± S.D. of triplicate samples of one experiment and representative of at least three independent experiments.

Cytokine Determination—Human TNF was determined in pooled cell-free supernatants of stimulated cells by sandwich enzyme-linked immunosorbent assay using monoclonal mouse antibody against human TNF and peroxidase-conjugated rabbit anti-human TNF antibody, respectively (Intex, Muttant, Switzerland), as stated in detail elsewhere (48). Human IL-8 was determined by sandwich enzyme-linked immunosorbent assay using IL-8 cytoset from BIOSOURCE exactly according to the manufacturer's protocol. Data shown are mean ± S.D. of triplicate samples of one representative experiment.

Fluorescence Resonance Energy Transfer Spectroscopy—The fluorescence resonance energy transfer (FRET) technique was used as a probe dilution assay (49) to obtain information on the intercalation of synthetic lipopeptides into liposomes resembling the lipid composition of the cytoplasmic membrane of macrophages (PL_M). For the FRET experiments, liposomes were double-labeled with NBD-PE and Rh-PE in chloroform [PL]:[NBD-PE]:[Rh-PE] at 100:1:1 molar ratios. The solvent was evaporated under a stream of nitrogen, and the lipids were resuspended in PBS, mixed thoroughly, and sonicated with a Branson sonicator for 1 min (1 ml of solution). Subsequently, the preparation was temperature-cycled at least twice between 4 and 56 °C, and each cycle was followed by intense vortexing for a few minutes and then stored at 4 °C for at least 12 h prior to measurement. A preparation of 900 µl of the double-labeled liposomes (10^–5 M) at 37 °C was excited at 470 nm (excitation wavelength of NBD-PE), and the intensities of the emission light of the donor NBD-PE (531 nm) and acceptor Rh-PE (593 nm) were measured simultaneously on the fluorescence spectrometer SPEX F1T11 (SPEX Instruments, Edison, NY). Compounds Pam₂CSK₄, Pam₃CSK₄, and lipolan (concentration 1 µM) were added to liposomes after 50 s. Because FRET spectroscopy is used here as a probe dilution assay, intercalation of unlabeled molecules causes an increase of the distance between donor and acceptor and thus leads to a reduced energy transfer. This again causes an increase of the donor and decrease of the acceptor intensities. For a qualitative analysis of experiments, the ratio of the intensities of the donor dye and the acceptor dye are plotted against time (denoted in the following as the FRET signal). The data shown are representative for three independent experiments.

Fourier Transform Infrared Spectroscopy—The infrared spectroscopic measurements were performed on an IFS-55 spectrometer (Bruker, Karlsruhe, Germany). For phase transition measurements, the lipid samples were placed between CaF₂ windows with a 12.5-µm Teflon spacer. Temperature scans were performed automatically between –10 and 70 °C with a heating rate of 0.6 °C/min. Every 3 °C, 50 interferograms were accumulated, apodized, Fourier-transformed, and converted to absorbance spectra. For the identification of particular functional groups, infrared spectra of the lipopeptides at 95% water concentration were analyzed. The vibrational bands typical for the hydrophobic region (symmetrical and antisymmetrical) _s and _as stretching vibration of –CH₂–groups around 2920 and 2850 cm^–1, respectively, in the IR spectra of lipopeptides are sensitive markers of acyl chain order.

X-ray Diffraction—X-ray diffraction measurements were performed at the European Molecular Biology Laboratory (EMBL) outstation at the Hamburg synchrotron radiation facility HASYLAB using the SAXS camera X33 (50). Diffraction patterns in the range of the scattering vector 0.1 < s < 1.0 nm^–1 (s = 2 sin /, 2 scattering angle and the wavelength = 0.15 nm) were recorded at 40 °C with exposure times of 1 min using an image plate detector with on-line readout (MAR345, MarResearch, Norderstedt, Germany). The s axis was calibrated with Ag-Behenate, which has a periodicity of 58.4 nm. The diffraction patterns were evaluated as described previously (51) assigning the spacing ratios of the main scattering maxima to defined three-dimensional structures. The lamellar and cubic structures are most relevant here. They are characterized by the following features. 1) Lamellar, the reflections are grouped in equidistant ratios, i.e. 1, 1/2, 1/3, 1/4, etc. of the lamellar repeat distance d_l. 2) Cubic, the different space groups of these nonlamellar three-dimensional structures differ in the ratio of their spacings. The relation between reciprocal spacing s_hkl = 1/d_hkl and lattice constant a is as follows: s_hkl = ((h² + k² + l²)/a)^1/2, where hkl = Miller indices of the corresponding set of plane. In the case of very weak diffraction maxima, resolution enhancement techniques were applied, in particular Fourier self-deconvolution as described by Kauppinen et al. (52).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Induction of TNF in Mononuclear Cells by Synthetic Lipopeptides—The ability of Pam₂CSK₄ and Pam₃CSK₄ to induce the production of TNF in human mononuclear cells was tested in comparison with LPS deep rough mutant Re (from strain R595 of Salmonella minnesota) (Fig. 2). Clearly, Re LPS is active down to 100 pg/ml, whereas the lipopeptides are active at least down to 10 ng/ml. The lipolanthionine peptide lipolan was completely inactive with respect to cytokine induction up to a concentration of 10 µg/ml (data not shown).

Synthetic Lipolanthionine Peptide Antagonizes Cell Activation by LPS—It was recently demonstrated that lipolan (Fig. 1) acts as an inhibitor of TLR2-mediated IL-8 secretion induced by the biologically active synthetic lipopeptide Pam₃CSK₄ (46). Because we did not observe any biological activity of lipolan in human mononuclear cells, we investigated the antagonistic activity of this TLR2 inhibitor with respect to stimulation by LPS (Fig. 3). Using human macrophages differentiated from peripheral blood mononuclear cells, we show here that lipolan is also able to antagonize cell activation by LPS in human macrophages, as shown by the reduction in TNF production in the presence of lipolan.

View larger version (50K): [in this window] [in a new window]   FIGURE 2. Activation of human macrophages by synthetic lipopeptides. Human mononuclear cells from healthy donors were stimulated with LPS and the lipopeptides Pam2CSK4 and Pam3CSK4 for 5 h, and TNF was determined in the supernatants. The data represent mean ± S.D. from one representative experiment of three, and the error bars result from the determination of TNF in triplicate.

View larger version (16K): [in this window] [in a new window]   FIGURE 3. Synthetic lipolanthionine peptide lipolan inhibits activation of human macrophages by LPS. Human macrophages were incubated with the biologically inactive lipolanthionine peptide lipolan at a concentration of 1 µg/ml for 30 min. Subsequently, LPS was added at the indicated concentrations, and cells were stimulated for 5 h before supernatants were harvested for the determination of TNF. Data shown are mean ± S.D. from one representative experiment of three, and the error bars result from the determination of TNF in triplicate. n.d., not detectable.

View larger version (17K): [in this window] [in a new window]   FIGURE 4. Antagonistic activity of synthetic lipolanthionine peptide does not depend on TLR2. HEK293 cells were transiently transfected with plasmids coding for huTLR4, huMD2, and huCD14 and incubated for 6 h to allow heterologous expression of the receptor proteins. Subsequently, cells were left unstimulated or stimulated with LPS (1 µg/ml) or TNF (10 ng/ml) in the absence or presence of lipolan (10 µM). After 24 h, supernatants were collected for the determination of the chemokine IL-8. Data shown are mean ± S.D. of triplicate samples of one experiment representative of at least three independent experiments. *, p < 0.05 (p value determined by Student's t test).

M

Interaction of Lipopeptides with Polymyxin B—The decapeptide polymyxin B (PMB) is a well known inactivator of endotoxin activity (54). We have found that concomitantly with this inhibition, PMB leads to a drastic fluidization of the acyl chains of LPS (55). We have tested the fluidity of Pam₃CSK₄ in the absence and presence of PMB, using the peak position of the symmetric stretching vibrational band at 2850 cm^–1 as a measure of lipid order (Fig. 6A). The data for the pure lipopeptide Pam₃CSK₄ are indicative of a broad gel to liquid crystalline phase transition with a mid-temperature around T_c = 35 °C. Addition of PMB leads to a drastic increase in the T_c value (to around 50 °C) with a sharpening of the transition. Accompanied by this is the strong decrease of the fluidity at 37 °C, as deduced from the decrease of the wave numbers (see arrow in Fig. 6A). This is the opposite of what has been reported for LPS, for which PMB induces a considerable fluidization (55).

We have furthermore tested the ability of PMB to influence the cytokine-inducing capacity of Pam₃CSK₄. Fig. 6B shows that at the two higher Pam₃CSK₄/PMB ratios there is a slight inhibition of the cytokine response. At the lowest ratio, however, there is no significant change. It can thus be concluded that there is little or no inhibition of the biological activity of the lipopeptides by PMB.

View larger version (18K): [in this window] [in a new window]   FIGURE 5. Synthetic lipopeptides interact with reconstituted phospholipid membranes. Incorporation of lipopeptides into liposomes PLM corresponded to the phospholipid composition of the macrophage membrane by FRET. The FRET signal ID/IA is plotted versus time. After 50 s, lipopeptides were added to the liposomes to a final concentration of 1 µM. Data are representative for three independent experiments.

View larger version (42K): [in this window] [in a new window]   FIGURE 6. Interaction of synthetic lipopeptides with polymyxin B. A, peak position of the symmetric stretching vibrational band of the methylene groups versus temperature for Pam3CSK4 in the absence and presence of PMB with Fourier-transform infrared spectroscopy. In the gel phase, the peak position lies around 2850 cm–1, and in the liquid crystalline phase the peak position lies between 2852.5 and 2853.0 cm–1. B, production of TNF from human mononuclear cells induced by Pam3CSK4 in the absence and presence of PMB. Data shown are one representative experiment of three, and the error bars (± S.D.) result from the determination of TNF in triplicate.

View larger version (19K): [in this window] [in a new window]   FIGURE 7. Molecular conformation of agonistic and antagonistic synthetic lipopeptides. Synchrotron radiation small angle x-ray diffraction patterns of the three lipopeptides at 40 °C and 95% water content. The band positions of the small peaks shown in A and B could be confirmed by applying Fourier self-deconvolution (52).

In contrast, the inhibitory lipolanthionine peptide (2R,6R)-Pam₂LanHda-Ser-(Lys)₄-NH₂ (lipolan) has a rather simple diffraction pattern (Fig. 7C), which can readily be interpreted as resulting from a multilamellar structure with a periodicity a_l = 6.30 nm and two further reflections at equidistant ratio a_l/2 and a_l/3.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Lipopeptides are produced by a broad variety of pathogenic microorganisms and have long been known as inducers of innate and adaptive immune responses by host lymphocytes. They have the capability to stimulate antigen-presenting cells, and these adjuvant effects have recently become important for the development and improvement of vaccines (41). Investigations in the bioactivity and the TLR2/1/6 requirement of a broad panel of synthetic lipopeptides have provided information on the chemical basis of cell activation by lipopeptides (30, 31, 57). However, in contrast to the well investigated lipopolysaccharides from Gram-negative bacteria, still very little is known about the molecular basis of lipopeptide recognition. This study is the first combined systematic physicochemical and biological analysis of lipopeptide structures from bacterial lipoproteins. There are considerable differences in the chemical structures between LPS and lipopeptides. The investigated LP compounds have a positively charged peptide backbone instead of the negatively charged sugar moiety of lipid A and only two or three acyl chains instead of six acyl chains in the lipid A expressing high biological activity. Nevertheless, we found some striking similarities to LPS. The lipopeptides showed high cytokine-inducing ability (Fig. 2) and had a strong preference to adopt cubic structures (Fig. 7, A and B), in particular with space group Q²²⁴ (also called Pn3m (56)), which has also been reported for lipid A (51). In contrast, the lipolanthionine peptide (2R,6R)-Pam₂LanHda-Ser(Lys)₄-NH₂ (lipolan) was found to adopt a lamellar aggregate structure (Fig. 7C) and as expected did not show cell activation analogously to what has been described for lamellar lipid A structures (38). Furthermore, in analogy to the potent endotoxin antagonist compound 406, a synthetic tetraacyl lipid A which assumes a lamellar structure (58), the lamellar compound lipolan was found to antagonize cell activation by LPS. Although lipolan has been described as an inhibitor for the TLR2-dependent cell activation by lipopeptides (46), the observation that this compound also antagonizes LPS was surprising. When we investigated the TLR dependence of the inhibition of cell activation by LPS, it turned out that the antagonistic activity was independent of TLR2 (Fig. 3), suggesting that besides TLR2 interaction other molecular mechanisms might hold true.

The structural and biological data are very surprising in view of the chemical structures of the compounds (Fig. 1). According to the shape concept of Israelachvili (36), who described the aggregate structures of amphiphiles on the basis of the ratio of the cross-sections of the hydrophilic and hydrophobic moiety, respectively, compounds with a higher value of the former should assume micellar or lamellar structures and in the inverse case nonlamellar cubic or H_II structures. The hydrophobic moiety of lipolan, which has three alkyl chains (2 x C₁₂ and 1 x C₁₆), can be expected to be larger than that of Pam₂CSK₄ which has two C₁₆ acyl chains, whereas the cross-sections of the hydrophilic moieties should be similar. One would thus have expected a stronger tendency toward an inverted cubic structure for lipolan than for Pam₂CSK₄, but the experimental results prove the opposite. From these data it can be concluded that when using the geometrical model of Israelachvili (36), one may have to take into account different water binding capacities in the head groups and the influence of the counterions, for example, but these cannot be readily be deduced from the primary chemical structures.

An important aspect of cell activation by LPS is its transport by the serum-protein LBP to the surface antigen CD14 on myelomonocytic cells and the transport and intercalation into target cell membranes (49, 53, 59). Investigation of the interaction of lipopeptides with phospholipid liposomes as a model for the lipid matrix of the cytoplasmic membrane showed that these compounds intercalate by themselves into phospholipid membranes (Fig. 5), whereas for endotoxins (agonistic as well as antagonistic structures) the transport protein LBP is necessary. The membrane activity of the lipopeptide lipolan might be the key to their antagonistic activity toward the TLR4-ligand LPS as the intercalated acyl chains of the lipopeptide might diffuse laterally to membrane proteins and thus interfere with assembly and signal transduction by the TLR-receptor complexes. It has been reported (60) that cell activation by di- and triacylated lipopeptides can be enhanced in the presence of LBP, suggesting that LBP might nevertheless play a role in lipopeptide cell activation. A recent publication (33) showed that the surface antigen CD36 is involved in the recognition of the diacylated lipopeptide MALP-2; however, cell activation by the triacylated Pam₃CSK₄ appeared to be independent of CD36. The authors suggest that CD36 functions analogously to CD14 by concentrating lipopeptides on the cell surface. Whether this involves transport by serum proteins such as LBP remains to be elucidated.

The importance of membrane binding of lipopeptides was demonstrated previously by Boncheva et al. (61) who investigated the behavior of a triacylated lipopeptide in phosphatidylcholine liposomes and monolayers. They found complete flexibility of the peptide part, thus enabling it to interact with the environment such as antibodies. Wolf et al. (62, 63) applied electron energy loss spectroscopy to study the interaction of cells with lipopeptides Pam₃Cys-Ser and fluorinated derivatives. They observed a distribution of the lipopeptides in different cell compartments, in particular also in the plasma membranes of macrophages and lymphoid cell lines. These data were also supported by findings with ultrathin cryosections of macrophages derived from bone marrow (64). The interaction of Pam₃Cys peptides was also investigated using spin labels and fluorescent markers with phosphatidylcholine and immune cells (65). It was found that the lipopeptide incorporates into the vesicles and cells, with exposure of the peptide moiety to the hydrophilic compartment and the Pam₃Cys part as membrane anchor. This membrane intercalation of the lipopeptide was assumed to be an early step of interaction and subsequent stimulation of immunocompetent cells, which is in complete accordance with the findings presented here.

The behavior of lipopeptides with PMB is completely different from that of endotoxins. In contrast to the fluidization observed when PMB interacts with endotoxins (55, 66), PMB clearly causes a rigidification of the acyl chains of the lipopeptide (Fig. 6A). The bioactivity of the lipopeptide is only very slightly reduced by PMB (Fig. 6B) in contrast to the massive reduction with endotoxins (54). These findings may be related to the positive charge of the lipopeptides, opposed to the negative charges of endotoxins. An interaction of the lipopeptides with the positively charged PMB could work via bridging of negative counterions (Cl^–), which in fact results in the change of the phase transition shown in Fig. 6A; in this interaction the aggregate structure of Pam₃CSK₄ is, however, not changed into a multilamellar structure, which has been found to be a necessary step for the inactivation for endotoxins (55).

Our data provide a physicochemical characterization of synthetic analogues of lipoprotein N termini and reveal that molecular and supramolecular conformations are important determinants for their bioactivity. This refers in particular to the structural prerequisites for agonistic or antagonistic activity. In addition, we found some striking characteristics of the interaction of lipopeptides with lipid membranes and their interaction with the antibiotic PMB, which are in sharp contrast to what has been described for LPS.

Only recently, a mutant of Staphylococcus aureus defective in the synthesis of lipopeptides was described (3). Isolation of lipoteichoic acid from these mutants resulted in a preparation that was dramatically attenuated in its biological activity compared with lipoteichoic acid preparations from wild type strains. The authors (3) concluded that not lipoteichoic acid but lipoproteins are the dominant immunobiologically active compounds in cell wall preparations of S. aureus. These findings once more underline the importance of lipopeptides as immunostimulatory active microbial compounds. The molecular principles underlying lipopeptide recognition are crucial for an understanding of the role of these molecules in health and disease.

	FOOTNOTES

 
^* This work was funded by Deutsche Forschungsgemeinschaft Grants SCHR 621/2-2 and Ul 68/3-1, the European Commission (Antimicrobial Endotoxin Neutralizing Peptides to Combat Infectious Diseases), and the Federal Ministry of Education and Research Project Biochance 0312662. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed. Tel.: 49-4537-188296; Fax: 49-4537-188632; E-mail: aschromm{at}fz-borstel.de.

² The abbreviations used are: LPS, lipopolysaccharide; FRET, fluorescence resonance energy transfer; IL, interleukin; LBP, lipopolysaccharide-binding protein; lipolan, lipolanthionine peptide (2R,6R)Pam₂LanHda-Ser-(Lys)₄-NH₂; LP, lipopeptide; Pam₂CSK_4, dipalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)₄; Pam₃CSK₄, tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)₄; PMB, polymyxin B; TLR, Toll-like receptor; TNF, tumor necrosis factor; PBS, phosphate-buffered saline; PE, phosphatidylethanolamine; NBD-PE, N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-PE; Rh-PE, N-(rhodamine B sulfonyl)-PE; PL, phospholipid; hu, human.

³ A. J. Ulmer, K.-H. Wiesmüller, T. Seyberth, and G. Jung, unpublished observations.

	ACKNOWLEDGMENTS

 
We thank K. Stephan, S. Groth, G. von Busse, and C. Hamann for performing the cytokine induction assay and the infrared and FRET measurements, respectively.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Gioffre, A., Caimi, K., Zumarraga, M. J., Meikle, V., Morsella, C., Bigi, F., Alito, A., Santangelo, M. P., Paolicchi, F., Romano, M. I., and Cataldi, A. (2006) J. Vet. Med. Ser. B 53, 34–41
2. Wardenburg, J. B., Williams, W. A., and Missiakas, D. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 13831–13836[Abstract/Free Full Text]
3. Hashimoto, M., Tawaratsumida, K., Kariya, H., Kiyohara, A., Suda, Y., Krikae, F., Kirikae, T., and Gotz, F. (2006) J. Immunol. 177, 3162–3169[Abstract/Free Full Text]
4. Kataoka, H., Yasuda, M., Iyori, M., Kiura, K., Narita, M., Nakata, T., and Shibata, K. (2006) Cell. Microbiol. 8, 1199–1209[CrossRef][Medline] [Order article via Infotrieve]
5. Yang, X. F., Alani, S. M., and Norgard, M. V. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11001–11006[Abstract/Free Full Text]
6. Melchers, F., Braun, V., and Galanos, C. (1975) J. Exp. Med. 142, 473–482[Abstract/Free Full Text]
7. Sellati, T. J., Waldrop, S. L., Salazar, J. C., Bergstresser, P. R., Picker, L. J., and Radolf, J. D. (2001) J. Immunol. 166, 4131–4140[Abstract/Free Full Text]
8. Braun, V., and Wolff, H. (1970) Eur. J. Biochem. 14, 387–391[Medline] [Order article via Infotrieve]
9. Underhill, D. M., and Ozinsky, A. (2002) Curr. Opin. Immunol. 14, 103–110[CrossRef][Medline] [Order article via Infotrieve]
10. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., RicciardiCastagnoli, P., Layton, B., and Beutler, B. (1998) Science 282, 2085–2088[Abstract/Free Full Text]
11. Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., and Kimoto, M. (1999) J. Exp. Med. 189, 1777–1782[Abstract/Free Full Text]
12. Schromm, A. B., Lien, E., Henneke, P., Chow, J. C., Yoshimura, A., Heine, H., Latz, E., Monks, B. G., Schwartz, D. A., Miyake, K., and Golenbock, D. T. (2001) J. Exp. Med. 194, 79–88[Abstract/Free Full Text]
13. Delude, R. L., Savedra, R., Jr., Zhao, H., Thieringer, R., Yamamoto, S., Fenton, M. J., and Golenbock, D. T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9288–9292[Abstract/Free Full Text]
14. Blondin, C., Le Dur, A., Cholley, B., Caroff, M., and Haeffner-Cavaillon, N. (1997) Eur. J. Immunol. 27, 3303–3309[Medline] [Order article via Infotrieve]
15. Correia, J. D., Soldau, K., Christen, U., Tobias, P. S., and Ulevitch, R. J. (2001) J. Biol. Chem. 276, 21129–21135[Abstract/Free Full Text]
16. Kielian, T. L., and Blecha, F. (1995) Immunopharmacology 29, 187–205[CrossRef][Medline] [Order article via Infotrieve]
17. El-Samalouti, V. T., Schletter, J., Chyla, I., Lentschat, A., Mamat, U., Brade, L., Flad, H.-D., Ulmer, A. J., and Hamann, L. (1999) FEMS Immunol. Med. Microbiol. 23, 259–269[CrossRef][Medline] [Order article via Infotrieve]
18. Triantafilou, K., Triantafilou, M., and Dedrick, R. L. (2001) Nat. Immun. 2, 338–345
19. Triantafilou, M., Brandenburg, K., Gutsmann, T., Seydel, U., and Triantafilou, K. (2002) Crit. Rev. Immunol. 22, 251–268[Medline] [Order article via Infotrieve]
20. Triantafilou, M., Miyake, K., Golenbock, D. T., and Triantafilou, K. (1999) J. Cell Sci. 115, 2603–2611
21. Iontcheva, I., Amar, S., Zawawi, K. H., Kantarci, A., and Van Dyke, T. E. (2004) Infect. Immun. 72, 2312–2320[Abstract/Free Full Text]
22. Blunck, R., Scheel, O., Mueller, M., Brandenburg, K., Seitzer, U., and Seydel, U. (2001) J. Immunol. 166, 1009–1015[Abstract/Free Full Text]
23. Gutsmann, T., Mueller, M., Carroll, S. F., MacKenzie, R. C., Wiese, A., and Seydel, U. (2001) Infect. Immun. 69, 6942–6950[Abstract/Free Full Text]
24. Mueller, M., Scheel, O., Lindner, B., Gutsmann, T., and Seydel, U. (2002) J. Endotoxin Res. 9, 181–186
25. Heine, H., and Lien, E. (2003) Int. Arch. Allergy Immunol. 130, 180–192[CrossRef][Medline] [Order article via Infotrieve]
26. Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., Schroeder, L., and Aderem, A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 13766–13771[Abstract/Free Full Text]
27. Gantner, B. N., Simmons, R. M., Canavera, S. J., Akira, S., and Underhill, D. M. (2003) J. Exp. Med. 197, 1107–1117[Abstract/Free Full Text]
28. Viriyakosol, S., Fierer, J., Brown, G. D., and Kirkland, T. N. (2005) Infect. Immun. 73, 1553–1560[Abstract/Free Full Text]
29. Yadav, M., and Schorey, J. S. (2006) Blood 108, 3168–3175[Abstract/Free Full Text]
30. Buwitt-Beckmann, U., Heine, H., Wiesmueller, K. H., Jung, G., Brock, R., and Ulmer, A. J. (2005) FEBS J. 272, 6354–6364[CrossRef][Medline] [Order article via Infotrieve]
31. Buwitt-Beckmann, U., Heine, H., Wiesmuller, K. H., Jung, G., Brock, R., Akira, S., and Ulmer, A. J. (2006) J. Biol. Chem. 281, 9049–9057[Abstract/Free Full Text]
32. Liu, H., Komai-Koma, M., Xu, D., and Liew, F. Y. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 7048–7053[Abstract/Free Full Text]
33. Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zaehringer, U., and Beutler, B. (2005) Nature 433, 523–527[CrossRef][Medline] [Order article via Infotrieve]
34. Bessler, W. G., Cox, M., Lex, A., Suhr, B., Wiesmuller, K. H., and Jung, G. (1985) J. Immunol. 135, 1900–1905[Abstract]
35. Prass, W., Ringsdorf, H., Bessler, W., Wiesmuller, K. H., and Jung, G. (1987) Biochim. Biophys. Acta 900, 116–128[Medline] [Order article via Infotrieve]
36. Israelachvili, J. N. (1991) Intermolecular and Surface Forces, 2nd Ed., pp. 366–394, Academic Press, London
37. Rietschel, E. T., and Brade, H. (1992) Sci. Am. 267, 54–61[Medline] [Order article via Infotrieve]
38. Brandenburg, K., Mayer, H., Koch, M. H. J., Weckesser, J., Rietschel, E. Th., and Seydel, U. (1993) Eur. J. Biochem. 218, 555–563[Medline] [Order article via Infotrieve]
39. Brandenburg, K., and Wiese, A. (2004) Curr. Top. Med. Chem. 4, 1127–1146[CrossRef][Medline] [Order article via Infotrieve]
40. Reichel, F., Roelofsen, A. M., Geurts, H. P., Der Gaast, S. J., Feiters, M. C., and Boons, G. J. (2000) J. Org. Chem. 65, 3357–3366[CrossRef][Medline] [Order article via Infotrieve]
41. Seydel, U., Hawkins, L., Schromm, A. B., Heine, H., Scheel, O., Koch, M. H., and Brandenburg, K. (2003) Eur. J. Immunol. 33, 1586–1592[CrossRef][Medline] [Order article via Infotrieve]
42. Brandenburg, K., Hawkins, L., Garidel, P., Andrä, J., Müller, M., Heine, H., Koch, M. H. J., and Seydel, U. (2004) Biochemistry 43, 4039–4046[CrossRef][Medline] [Order article via Infotrieve]
43. Metzger, J., Wiesmuller, K. H., Schaude, R., Bessler, W. G., and Jung, G. (1991) Int. J. Pept. Protein Res. 37, 46–57[Medline] [Order article via Infotrieve]
44. Wiesmueller, K. H., Bessler, W. G., and Jung, G. (1992) Int. J. Pept. Protein Res. 40, 255–260[Medline] [Order article via Infotrieve]
45. Metzger, J. W., Beck-Sickinger, A. G., Loleit, M., Eckert, M., Bessler, W. G., and Jung, G. (1995) J. Pept. Sci. 1, 184–190[CrossRef][Medline] [Order article via Infotrieve]
46. Seyberth, T., Voss, S., Brock, R., Wiesmueller, K. H., and Jung, G. (2006) J. Med. Chem. 49, 1754–1765[CrossRef][Medline] [Order article via Infotrieve]
47. Galanos, C., Lüderitz, O., and Westphal, O. (1969) Eur. J. Biochem. 9, 245–249[Medline] [Order article via Infotrieve]
48. Mueller, M., Brandenburg, K., Dedrick, R., Schromm, A. B., and Seydel, U. (2005) J. Immunol. 174, 1091–1096[Abstract/Free Full Text]
49. Schromm, A. B., Brandenburg, K., Rietschel, E. Th., Flad, H.-D., Carroll, S. F., and Seydel, U. (1996) FEBS Lett. 399, 267–271[CrossRef][Medline] [Order article via Infotrieve]
50. Koch, M. H. J. (1988) Makromol. Chem. Macromol. Symp. 15, 79–90
51. Brandenburg, K., Richter, W., Koch, M. H. J., Meyer, H. W., and Seydel, U. (1998) Chem. Phys. Lipids 91, 53–69[CrossRef][Medline] [Order article via Infotrieve]
52. Kauppinen, J. K., Moffat, D. J., Mantsch, H. H., and Cameron, D. G. (1981) Appl. Spectrosc. 35, 271–276
53. Gutsmann, T., Schromm, A. B., Koch, M. H. J., Kusumoto, S., Fukase, K., Oikawa, M., Seydel, U., and Brandenburg, K. (2000) Phys. Chem. Chem. Phys. 2, 4521–4528
54. Gough, M., Hancock, R. E. W., and Kelly, N. M. (1996) Infect. Immun. 64, 4922–4927[Abstract]
55. Brandenburg, K., Moriyon, I., Arraiza, M. D., Lehwark-Yvetot, G., Koch, M. H. J., and Seydel, U. (2002) Thermochim. Acta 382, 189–198
56. Luzzati, V., Vargas, R., Mariani, P., Gulik, A., and Delacroix, H. (1993) J. Mol. Biol. 229, 540–551[CrossRef][Medline] [Order article via Infotrieve]
57. Spohn, R., Buwitt-Beckmann, U., Brock, R., Jung, G., Ulmer, A. J., and Wiesmueller, K. H. (2004) Vaccine 22, 2494–2499[CrossRef][Medline] [Order article via Infotrieve]
58. Schromm, A. B., Brandenburg, K., Loppnow, H., Moran, A. P., Koch, M. H. J., Rietschel, E. Th., and Seydel, U. (2000) Eur. J. Biochem. 267, 2008–2013[Medline] [Order article via Infotrieve]
59. Mathison, J., Wolfson, E., Steinemann, S., Tobias, P., and Ulevitch, R. (1993) J. Clin. Investig. 92, 2053–2059[Medline] [Order article via Infotrieve]
60. Schroder, N. W., Heine, H., Alexander, C., Manukyan, M., Eckert, J., Hamann, L., Gobel, U. B., and Schumann, R. R. (2004) J. Immunol. 173, 2683–2691[Abstract/Free Full Text]
61. Boncheva, M., Duschl, C., Beck, W., Jung, G., and Vogel, H. (1996) Langmuir 12, 5636–5642
62. Wolf, B., Hauschildt, S., Uhl, B., Metzger, J., Jung, G., and Bessler, W. G. (1989) Immunol. Lett. 20, 121–126[CrossRef][Medline] [Order article via Infotrieve]
63. Wolf, B., Uhl, B., Hauschildt, S., Metzger, J., Jung, G., and Bessler, W. G. (1989) Immunobiology 180, 93–100[Medline] [Order article via Infotrieve]
64. Uhl, B., Wolf, B., Schwinde, A., Metzger, J., Jung, G., Bessler, W. G., and Hauschildt, S. (1991) J. Leukocyte Biol. 50, 10–18[Abstract]
65. Metzger, J. W., Sawyer, W. H., Wille, B., Biesert, L., Bessler, W. G., and Jung, G. (1993) Biochim. Biophys. Acta 1149, 29–39[Medline] [Order article via Infotrieve]
66. Brandenburg, K., David, A., Howe, J., Koch, M. H., Andra, J., and Garidel, P. (2005) Biophys. J. 88, 1845–1858

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. Howe, P. Garidel, M. Roessle, W. Richter, C. Alexander, K. Fournier, J. P. Mach, T. Waelli, R. M. Gorczynski, A. J. Ulmer, et al. Structural investigations into the interaction of hemoglobin and part structures with bacterial endotoxins Innate Immunity, February 1, 2008; 14(1): 39 - 49. [Abstract] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 282/15/11030    most recent M700287200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schromm, A. B. Articles by Brandenburg, K. Search for Related Content PubMed PubMed Citation Articles by Schromm, A. B. Articles by Brandenburg, K. Social Bookmarking                      What's this?